Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma

Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma

Copyright © 2019. Published by Elsevier Inc.

Détails bibliographiques
Publié dans:Clinical immunology (Orlando, Fla.). - 1999. - 203(2019) vom: 15. Juni, Seite 154-161
Auteur principal: Sciullo, Paula Di (Auteur)
Autres auteurs: Menay, Florencia, Cocozza, Federico, Gravisaco, María José, Waldner, Claudia I, Mongini, Claudia
Format: Article en ligne
Langue:English
Publié: 2019
Accès à la collection:Clinical immunology (Orlando, Fla.)
Sujets:Journal Article Research Support, Non-U.S. Gov't CD40 Imiquimod T-cell lymphoma-vaccine TLR Adjuvants, Immunologic Antigens, Neoplasm Cancer Vaccines Cell Extracts plus... Toll-Like Receptor 7 P1QW714R7M
Accès en ligne Volltext